SynCore Biotechnology Co Ltd-製薬・医療分野:企業M&A・提携分析

【英語タイトル】SynCore Biotechnology Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA8013432)・商品コード:DATA8013432
・発行会社(調査会社):GlobalData
・発行日:2017年11月28日
・ページ数:23
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
SynCore Biotechnology Co Ltd (SynCore), a subsidiary of Sinphar Pharmaceutical Co Ltd is a biopharmaceutial company that utilizes and in-licenses technologies to develop new drugs. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05. Its SB01 drug is a new chemical entity (NCE), which is developed for treating solid tumors, head and neck cancer. SynCore provides SB02 for solid tumors; and SB04 for age-related macular degeneration. The company’s SB05 is a composition of cytostatic drug paclitaxel combined with neutral and positive lipids is being developed for breast cancer. Its marketed product SB03 is an ointment developed for the treatment of external genital warts. The company partners with other pharmaceutical companies, non-profit foundation and biotechnology company. It operates through its offices in I-Lan and Taipei, Taiwan. SynCore is headquartered in Yilan, Taiwan.

SynCore Biotechnology Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 10
Partnerships 11
SynCore Biotech Enters into Co-Development Contract with Aju Pharm 11
National Taiwan University Hospital Forms Joint Venture with SynCore Biotech 12
Licensing Agreements 13
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 13
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 14
MediGene Enters Into Licensing Agreement With Syncore Biotech For Veregen 15
Equity Offering 16
SynCore Biotech to Raise USD8.7 Million in Rights Offering of Shares 16
SynCore Biotech to Raise USD1.1 Million in Public Offering of Shares 17
SynCore Biotech to Raise Funds through Public Offering of Shares 18
SynCore Biotech to Raise Funds through Rights Offering of Shares 19
SynCore Biotechnology Co Ltd – Key Competitors 20
SynCore Biotechnology Co Ltd – Key Employees 21
SynCore Biotechnology Co Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SynCore Biotechnology Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 10
SynCore Biotech Enters into Co-Development Contract with Aju Pharm 11
National Taiwan University Hospital Forms Joint Venture with SynCore Biotech 12
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 13
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 14
MediGene Enters Into Licensing Agreement With Syncore Biotech For Veregen 15
SynCore Biotech to Raise USD8.7 Million in Rights Offering of Shares 16
SynCore Biotech to Raise USD1.1 Million in Public Offering of Shares 17
SynCore Biotech to Raise Funds through Public Offering of Shares 18
SynCore Biotech to Raise Funds through Rights Offering of Shares 19
SynCore Biotechnology Co Ltd, Key Competitors 20
SynCore Biotechnology Co Ltd, Key Employees 21
SynCore Biotechnology Co Ltd, Other Locations 22
SynCore Biotechnology Co Ltd, Joint Venture 22

★調査レポート[SynCore Biotechnology Co Ltd-製薬・医療分野:企業M&A・提携分析] (コード:DATA8013432)販売に関する免責事項を必ずご確認ください。
★調査レポート[SynCore Biotechnology Co Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆